-
Something wrong with this record ?
Immune activation of the monocyte-derived dendritic cells using patients own circulating tumor cells
K. Kolostova, E. Pospisilova, R. Matkowski, J. Szelachowska, V. Bobek
Language English Country Germany
Document type Journal Article
NLK
PubMed Central
from 1982
ProQuest Central
from 1997-03-01 to 1 year ago
Medline Complete (EBSCOhost)
from 2000-04-01 to 1 year ago
Health & Medicine (ProQuest)
from 1997-03-01 to 1 year ago
Public Health Database (ProQuest)
from 1997-03-01 to 1 year ago
- MeSH
- Dendritic Cells * metabolism MeSH
- Granulocyte-Macrophage Colony-Stimulating Factor pharmacology MeSH
- Interleukin-4 pharmacology MeSH
- Interleukin-6 pharmacology MeSH
- Humans MeSH
- Monocytes * metabolism MeSH
- Neoplastic Cells, Circulating * metabolism MeSH
- Prostaglandins E pharmacology MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
BACKGROUND: Dendritic cell (DC) therapy counts to the promising strategies how to weaken and eradicate cancer disease. We aimed to develop a good manufacturing practice (GMP) protocol for monocyte-derived DC (Mo-DC) maturation using circulating tumor cells lysates with subsequent experimental T-cell priming in vitro. METHODS: DC differentiation was induced from a population of immunomagnetically enriched CD14 + monocytes out of the leukapheresis samples (n = 6). The separation was provided automatically, in a closed bag system, using CliniMACS Prodigy® separation protocols (Miltenyi Biotec). For differentiation and maturation of CD14 + cells, DendriMACs® growing medium with supplements (GM-CSF, IL-4, IL-6, IL-1B, TNFa, PGE) was used. Immature Mo-DCs were loaded with autologous circulating tumor cell (CTCs) lysates. Autologous CTCs were sorted out by size-based filtration (MetaCell®) of the leukapheresis CD14-negative fraction. A mixture of mature Mo-DCs and autologous non-target blood cells (NTBCs) was co-cultured and the activation effect of mature Mo-DCs on T-cell activation was monitored by means of multimarker gene expression profiling. RESULTS: New protocols for mMo-DC production using automatization and CTC lysates were introduced including a feasible in vitro assay for mMo-DC efficacy evaluation. Gene expression analysis revealed elevation for following genes in NTBC (T cells) subset primed by mMo-DCs: CD8A, CD4, MKI67, MIF, TNFA, CD86, and CD80 (p ≤ 0.01). CONCLUSION: Summarizing the presented data, we might conclude mMo-DCs were generated using CliniMACS Prodigy® machine and CTC lysates in a homogenous manner showing a potential to generate NTBC activation in co-cultures. Identification of the activation signals in T-cell population by simple multimarker-qPCRs could fasten the process of effective mMo-DC production.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22032517
- 003
- CZ-PrNML
- 005
- 20230131150812.0
- 007
- ta
- 008
- 230120s2022 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00262-022-03189-2 $2 doi
- 035 __
- $a (PubMed)35471603
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Kolostova, Katarina $u Laboratory of Personalized Medicine, Oncology Clinic, University Hospital Kralovske Vinohrady, Srobarova 50, 10034, Prague, Czech Republic
- 245 10
- $a Immune activation of the monocyte-derived dendritic cells using patients own circulating tumor cells / $c K. Kolostova, E. Pospisilova, R. Matkowski, J. Szelachowska, V. Bobek
- 520 9_
- $a BACKGROUND: Dendritic cell (DC) therapy counts to the promising strategies how to weaken and eradicate cancer disease. We aimed to develop a good manufacturing practice (GMP) protocol for monocyte-derived DC (Mo-DC) maturation using circulating tumor cells lysates with subsequent experimental T-cell priming in vitro. METHODS: DC differentiation was induced from a population of immunomagnetically enriched CD14 + monocytes out of the leukapheresis samples (n = 6). The separation was provided automatically, in a closed bag system, using CliniMACS Prodigy® separation protocols (Miltenyi Biotec). For differentiation and maturation of CD14 + cells, DendriMACs® growing medium with supplements (GM-CSF, IL-4, IL-6, IL-1B, TNFa, PGE) was used. Immature Mo-DCs were loaded with autologous circulating tumor cell (CTCs) lysates. Autologous CTCs were sorted out by size-based filtration (MetaCell®) of the leukapheresis CD14-negative fraction. A mixture of mature Mo-DCs and autologous non-target blood cells (NTBCs) was co-cultured and the activation effect of mature Mo-DCs on T-cell activation was monitored by means of multimarker gene expression profiling. RESULTS: New protocols for mMo-DC production using automatization and CTC lysates were introduced including a feasible in vitro assay for mMo-DC efficacy evaluation. Gene expression analysis revealed elevation for following genes in NTBC (T cells) subset primed by mMo-DCs: CD8A, CD4, MKI67, MIF, TNFA, CD86, and CD80 (p ≤ 0.01). CONCLUSION: Summarizing the presented data, we might conclude mMo-DCs were generated using CliniMACS Prodigy® machine and CTC lysates in a homogenous manner showing a potential to generate NTBC activation in co-cultures. Identification of the activation signals in T-cell population by simple multimarker-qPCRs could fasten the process of effective mMo-DC production.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a dendritické buňky $x metabolismus $7 D003713
- 650 _2
- $a faktor stimulující granulocyto-makrofágové kolonie $x farmakologie $7 D016178
- 650 _2
- $a interleukin-4 $x farmakologie $7 D015847
- 650 _2
- $a interleukin-6 $x farmakologie $7 D015850
- 650 12
- $a monocyty $x metabolismus $7 D009000
- 650 12
- $a nádorové cirkulující buňky $x metabolismus $7 D009360
- 650 _2
- $a prostaglandiny E $x farmakologie $7 D011458
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Pospisilova, Eliska $u Laboratory of Personalized Medicine, Oncology Clinic, University Hospital Kralovske Vinohrady, Srobarova 50, 10034, Prague, Czech Republic
- 700 1_
- $a Matkowski, Rafal $u Department of Oncology, Wrocław Medical University, Wrocław, Poland $u Breast Cancer Unit, Lower Silesian Oncology, Pulmonology and Hematology Center, Plac Hirszfelda 12, 54-413, Wrocław, Poland
- 700 1_
- $a Szelachowska, Jolanta $u Department of Oncology, Wrocław Medical University, Wrocław, Poland $u Breast Cancer Unit, Lower Silesian Oncology, Pulmonology and Hematology Center, Plac Hirszfelda 12, 54-413, Wrocław, Poland
- 700 1_
- $a Bobek, Vladimir $u Laboratory of Personalized Medicine, Oncology Clinic, University Hospital Kralovske Vinohrady, Srobarova 50, 10034, Prague, Czech Republic. vbobek@centrum.cz $u 3rd Department of Surgery University Hospital Motol and 1st Faculty of Medicine, Charles University, V Uvalu 84, 15006, Prague, Czech Republic. vbobek@centrum.cz $u Department of Thoracic Surgery, Masaryk's Hospital, Krajska Zdravotni a.s., Socialni pece 3316/12A, 40113, Usti nad Labem, Czech Republic. vbobek@centrum.cz $u Department of Thoracic Surgery, Lower Silesian Oncology, Pulmology and Hematology Center and Medical University Wroclaw, Grabiszynska 105, 53-413, Wrocław, Poland. vbobek@centrum.cz $1 https://orcid.org/0000000289743577
- 773 0_
- $w MED00001041 $t Cancer immunology, immunotherapy : CII $x 1432-0851 $g Roč. 71, č. 12 (2022), s. 2901-2911
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35471603 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230120 $b ABA008
- 991 __
- $a 20230131150808 $b ABA008
- 999 __
- $a ok $b bmc $g 1891339 $s 1183852
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2022 $b 71 $c 12 $d 2901-2911 $e 20220426 $i 1432-0851 $m Cancer immunology and immunotherapy $n Cancer Immunol Immunother $x MED00001041
- LZP __
- $a Pubmed-20230120